A Phase 3, Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain for Which Parenteral Opioid Therapy is Warranted

Trial Profile

A Phase 3, Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain for Which Parenteral Opioid Therapy is Warranted

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2017

At a glance

  • Drugs Oliceridine (Primary)
  • Indications Pain; Postoperative pain
  • Focus Adverse reactions; Registrational
  • Acronyms ATHENA-1
  • Sponsors Trevena
  • Most Recent Events

    • 02 Nov 2017 According to a Trevena media release, company announced that it has recently submitted its New Drug Application (NDA) for OLINVOTM (oliceridine injection) to the U.S. Food and Drug Administration (FDA). Based on the data from APOLLO, ATHENA, other phase II and Phase III studies.
    • 20 Jul 2017 According to a Trevena media release, data from this study will be presented at 2017 Analyst Day.
    • 20 Jul 2017 According to a Trevena media release, based on the data from this study company plans to submit New Drug Application for OLINVOTM (oliceridine injection) is expected in September or October 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top